^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DCC-3084

    i
    Other names: DCC-3084, DCC3084, DCC 3084
    Associations

    News

    Trials
    Company:
    Ono Pharmaceutical
    Drug class:
    pan-RAF inhibitor
    Related drugs:
    Associations

    News

    Trials
    27d
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1, N=29, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=140 --> 29 | Trial completion date: Aug 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Feb 2026; Trial terminated due to a business decision, not based on any safety concerns.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
    |
    BRAF mutation
    |
    DCC-3084
    6ms
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DCC-3084
    almost2years
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Deciphera Pharmaceuticals LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    DCC-3084
    2years
    Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Deciphera Pharmaceuticals LLC
    New P1/2 trial
    |
    DCC-3084
    3years
    DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models (AACR 2023)
    The Switch Control inhibitor DCC-3084 broadly inhibits Class I, II and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers leading to tumor regression in preclinical models. The overall preclinical profile of DCC-3084 supports IND-enabling activities towards clinical development in a key area of unmet medical need in RAS and RAF mutant cancers.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RAS mutation • BRAF fusion • KRAS Q61K
    |
    DCC-3084